169 related articles for article (PubMed ID: 16402596)
1. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
[No Abstract] [Full Text] [Related]
2. Prostate cancer--the therapeutic challenge of locally advanced disease.
Blasko JC; Lange PH
N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
[No Abstract] [Full Text] [Related]
3. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
4. Treatment of prostate cancer with goserelin and radiotherapy.
Vicini FA; Kini VR; Martinez AA
N Engl J Med; 1997 Dec; 337(23):1693-4. PubMed ID: 9411236
[No Abstract] [Full Text] [Related]
5. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
6. [Update of the study on survival with early hormonal therapy associated with radiotherapy (EORTC 22863 Study) in patients with advanced prostatic cancer. Interview with Michel Bolla].
Bolla M
Recenti Prog Med; 2001 Feb; 92(2):128-9. PubMed ID: 11294104
[No Abstract] [Full Text] [Related]
7. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.
Fleshner N; Keane TE; Lawton CA; Mulders PF; Payne H; Taneja SS; Morris T
Prostate Cancer Prostatic Dis; 2008; 11(1):46-52. PubMed ID: 17607304
[TBL] [Abstract][Full Text] [Related]
8. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
[TBL] [Abstract][Full Text] [Related]
9. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
[No Abstract] [Full Text] [Related]
10. Treatment of prostate cancer with goserelin and radiotherapy.
Schoen SS
N Engl J Med; 1997 Dec; 337(23):1693; author reply 1694. PubMed ID: 9411235
[No Abstract] [Full Text] [Related]
11. Treating prostate cancer: another step forward.
Harv Mens Health Watch; 1998 May; 2(10):7. PubMed ID: 9577263
[No Abstract] [Full Text] [Related]
12. Advancements in radiotherapy and improved outcomes in prostate cancer.
Milito SJ; Thomas CR; Turrisi AT
J S C Med Assoc; 1998 Jun; 94(6):257-62. PubMed ID: 9648407
[No Abstract] [Full Text] [Related]
13. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Di Silverio F; Serio M; Costantini A
J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
[No Abstract] [Full Text] [Related]
14. [Integrated (surgical and hormonal) treatment of advanced prostatic carcinoma. Comment on the study and the interview with Edward M. Messing].
Prayer Galetti T
Recenti Prog Med; 2001 Feb; 92(2):126-7. PubMed ID: 11294103
[No Abstract] [Full Text] [Related]
15. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
Milecki P
Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
[TBL] [Abstract][Full Text] [Related]
16. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
Shipley WU; Desilvio M; Pilepich MV; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1162-7. PubMed ID: 16427211
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
18. Patient treatment preference in metastatic prostate cancer.
Creagh T
Ir Med J; 1996; 89(1):12. PubMed ID: 8984072
[TBL] [Abstract][Full Text] [Related]
19. Hormonal administration in prostate cancer: a caring approach.
Ebersole ME
Urol Nurs; 1996 Mar; 16(1):23-6. PubMed ID: 8826392
[No Abstract] [Full Text] [Related]
20. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack A; Horwitz EM
Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
